<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916045</url>
  </required_header>
  <id_info>
    <org_study_id>07CC12</org_study_id>
    <secondary_id>REC - 07/H0808/193</secondary_id>
    <secondary_id>EudraCT - 2007-001657-26</secondary_id>
    <nct_id>NCT00916045</nct_id>
  </id_info>
  <brief_title>Pilot Study of Unrelated Cord Blood Transplantation</brief_title>
  <official_title>Pilot Study of Unrelated Cord Blood Transplantation in Patients With Poor Risk Haematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College Hospital NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and feasibility of unrelated double and
      single cord blood transplantation in patients with haematological malignancies using
      reduced-intensity or myeloablative conditioning regimens.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment issues
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related mortality at day 100</measure>
    <time_frame>Day 100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival at one year post-transplant for each cohort</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>Days 14 (myeloblative conditioning only), 28, 56, 100 and months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutrophil engraftment by day 42</measure>
    <time_frame>Days 14, 28 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of platelet engraftment by 6 months</measure>
    <time_frame>Days 14, 28, 56, 100 and month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade II-IV and III-IV acute GVHD</measure>
    <time_frame>Days 28, 56, 100 and months 6, 9, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD during the first year</measure>
    <time_frame>Day 100 and months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One year overall survival for each treatment cohort</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of systemic infections</measure>
    <time_frame>Twice a week pre-transplant to day 100 then weekly or as clinically indicated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CMV, adenovirus and EBV activation</measure>
    <time_frame>Twice a week pre-transplant to day 100 then weekly or as clinically indicated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>Days 14, 28, 56, 100 and months 6, 9, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of EBV infection and immunity following cord blood transplantation</measure>
    <time_frame>Days 14, 28, 56, 100 and months 6, 9 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The development (if any) of transplant associated post transplant lymphoproliferative disease (PTLD)</measure>
    <time_frame>Days 14, 28, 56, 100 and months 6, 9 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify any possible predictive markers for patients most at risk of PTLD development</measure>
    <time_frame>Days 14, 28, 56, 100 and months 6, 9 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Pre-transplant and months 6, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of one year relapse or disease progression for each treatment cohort</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Lymphoblastic, Acute</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous busulphan</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
    <other_name>Busilvex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <arm_group_label>Myeloblative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluCyTBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <arm_group_label>Reduced intensity conditioning regimen - FluMel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE INCLUSION CRITERIA:

        In general this encompasses all haematological disorders where a volunteer unrelated donor
        transplant is clinically indicated.

          1. Acute, chronic leukaemia or myelodysplastic syndrome for which allogeneic
             transplantation is considered as the best treatment option.

               1. Acute myeloid leukaemia (AML) in first complete remission (CR1) with one of the
                  following characteristics:

                    -  High risk cytogenetic or molecular alterations (e.g. t(9;22), deletion
                       7/7q-, monosomy 5 or del(5q), 3q26 alterations, complex karyotype [3 or more
                       anomalies], p53 alterations, 11q23 especially t(6;11) abnormalities, FLT-3
                       ITD)

                    -  Leukocytes at diagnosis &gt; 50 x109/l (except in cases with good prognosis
                       molecular rearrangements for which leukocytes should be &gt; 100 x 109/l)

               2. Myelodysplastic syndromes

                    -  International Prognosis Index (IPSS) above 1 (intermediate group 2 or high
                       risk)

                    -  IPSS 0 or 0.5 in the presence of cytopenias requiring treatment.

               3. Therapy related AML or MDS in first CR

               4. AML or MDS in second (CR2) or subsequent CR

               5. Ph'-positive chronic myeloid leukaemia

             i. In first chronic phase if refractory and/or intolerance to tyrosine kinase
             inhibitors is clearly demonstrated ii. In second chronic phase

          2. Acute lymphoblastic leukaemia (ALL)

             a. In CR1 with one of the following characteristics: i. Very high risk chromosome or
             molecular alterations (e.g. t(9;22), t(4;11), complex karyotype in adults, bcr/abl
             rearrangements, MLL rearrangements) ii. Slow response to induction treatment defined
             as the presence of &gt;10% blasts in bone marrow at day 14 of induction treatment iii.
             Adults aged &gt; 30 years iv. Adults with B ALL cell line with a number of leukocytes at
             diagnosis &gt;25 x 109/L or T ALL cell line with a number of leukocytes at diagnosis
             &gt;100X109/L

             b. In CR2 or subsequent CR

          3. Non-Hodgkin's lymphoma

               1. Follicular NHL: in second or subsequent complete or partial remission

               2. Mantle cell NHL: in second or subsequent complete or partial remission

               3. High grade NHL: in second complete or very good partial remission

          4. Hodgkin's disease

             a. in second or subsequent complete or partial remission

          5. Chronic lymphocytic leukaemia.

               1. in second or subsequent remission

               2. with adverse risk prognostic features in first remission

          6. Acquired bone marrow failure syndromes

          7. Other haematological malignancies for which UD bone marrow transplantation is
             indicated

        PATIENT SELECTION

        Inclusion criteria: myeloablative conditioning regimen

          1. Aged under 35 years and greater than 18 years

          2. Absence of HLA compatible related donor.

          3. Need for an urgent transplantation or absence of HLA-compatible VUD after searching
             the international registries.

          4. Patients with a HLA-compatible VUD but whose donor is considered by the
             transplantation centre as unsuitable will also be eligible.

          5. Availability of suitable UD-UCB unit/s.

          6. Informed consent.

        Exclusion criteria: myeloablative conditioning regimen

          1. Patients with an available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor or 10/10
             unrelated bone marrow donor

          2. ECOG performance status worse than 2

          3. Cardiac insufficiency requiring treatment, symptomatic coronary artery disease or LVEF
             less than 40%.

          4. Hepatic disease, with total bilirubin above 20umol/l or AST &gt; 3 times upper limit of
             normal.

          5. Severe hypoxaemia, pO2 &lt; 70 mm Hg, with decreased DLCO &lt; 70% of predicted; or mild
             hypoxemia, pO2 &lt; 80 mm Hg with severely decreased DLCO &lt; 60% of predicted.

          6. Impaired renal function (creatinine &gt; 2 times upper limit of normal or creatinine
             clearance &lt; 50% for age, gender, weight).

          7. Patients who have received previous treatment with Thymoglobulin®

          8. HIV or HTLV positive patients.

          9. Female patients who are pregnant or breast feeding due to risks to foetus from
             conditioning regimen and potential risks to nursing infants.

         10. Life expectancy severely limited by diseases other than the disease indication for
             transplant

         11. Serious concurrent untreated infection e.g. active tuberculosis, mycoses or viral
             infection

         12. Serious psychiatric/ psychological disorders

         13. Absence of /inability to provide informed consent

         14. Serious diseases that prevent treatments with chemotherapy

         15. Myelofibrosis

        Inclusion criteria: reduced-intensity conditioning regimen (For both FluMel &amp; FluCyTBI
        regimens):

          1. Age under 70 years and older than 18 years

          2. Absence of HLA compatible related donor.

          3. Need for an urgent transplantation or absence of HLA-compatible VUD after searching
             the international registries.

          4. Patients with a HLA-compatible VUD but whose donor is considered by the
             transplantation centre as unsuitable will also be eligible.

          5. Availability of suitable UD-UCB unit/s.

          6. Informed consent.

        Exclusion Criteria: reduced-intensity conditioning regimen (For both FluMel &amp; FluCyTBI
        regimens):

          1. Patients with an available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor or 10/10
             unrelated bone marrow donor

          2. ECOG performance status worse than 2

          3. Cardiac insufficiency requiring treatment, symptomatic coronary artery disease or LVEF
             less than 35%.

          4. Hepatic disease, with total bilirubin greater than 2 times upper limit of normal or
             AST &gt; 5 times upper limit of normal.

          5. Severe hypoxaemia, pO2 &lt; 70 mm Hg, with decreased DLCO &lt; 50% of predicted; or mild
             hypoxemia, pO2 &lt; 80 mm Hg with severely decreased DLCO &lt; 50% of predicted.

          6. Impaired renal function (creatinine &gt; 2 times upper limit of normal or creatinine
             clearance &lt; 50% for age, gender, weight).

          7. Previous irradiation that precludes the safe administration of an additional dose of
             200 cGy of total body irradiation (TBI).

          8. Patients who have received previous treatment with Thymoglobulin®

          9. HIV or HTLV positive patients.

         10. Female patients who are pregnant or breast feeding due to risks to foetus from
             conditioning regimen and potential risks to nursing infants.

         11. Life expectancy severely limited by diseases other than the disease indication for
             transplant

         12. Serious concurrent uncontrolled infection e.g. active tuberculosis, mycoses or viral
             infection

         13. Serious psychiatric/ psychological disorders

         14. Absence of /inability to provide informed consent

         15. Within 6 months of prior myeloablative transplant.

         16. Patients with acute leukaemia in morphological relapse/ persistent/ progressive
             disease

         17. Intermediate or high grade NHL, mantle cell NHL and Hodgkin's disease that is
             refractory or progressive on salvage therapy.

         18. Myelofibrosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Pagliuca, MBBS, MA, FRCP, FRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's College Hosptial NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>February 10, 2015</last_update_submitted>
  <last_update_submitted_qc>February 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dr Antonio Pagliuca</name_title>
    <organization>King's College Hospital NHS Foundation Trust</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

